Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Immunomodulating and neurotrophic effects reported for 1-oxorapamycins

April 26, 2002

Peptide derG provides protection against malaria, herpes and cancer

April 26, 2002

Interim phase II results for ISAtx-247 in renal transplantation

April 26, 2002

Complement inhibitor GAS-914 may protect against cytotoxic injury in xenotransplantation

April 26, 2002

Blockade of VLA-4 together with immunosuppression may help prevent transplant vasculopathy

April 26, 2002

Immunosuppressants and their application described by Merck

April 25, 2002

Genentech licenses Xenova's OX40/OX40 ligand technology

April 24, 2002

Go-ahead received for group A Streptococcus vaccine trial

April 17, 2002

AMD-3100 evaluated in healthy volunteers in combination with Neupogen

April 16, 2002

Product R to enter phase II as topical treatment for genital warts

April 16, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....